Business Wire

2025 Thales Data Threat Report Reveals Nearly 70% of Organizations Identify AI’s Fast-Moving Ecosystem as Top GenAI-Related Security Risk

Share

73% are investing in AI-specific security tools with either new or existing budgets. Malware remains top attack type since 2021; phishing rises to second, ransomware drops to third. 60% identified future decryption of today’s data and future encryption compromise as major concerns among quantum computing security threats.

Thales today announced the release of the 2025 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey conducted by S&P Global Market Intelligence 451 Research of more than 3,100 IT and security professionals in 20 countries across 15 industries. This year’s report found that nearly 70% of organizations view the rapid pace of AI development1 —particularly in generative AI—as the leading security concern related to its adoption, followed by lack of integrity (64%) and trustworthiness (57%).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520290850/en/

©Thales

The 2025 Thales Data Threat Report results reveal a major focus on the transformative impact of AI, especially GenAI, which relies heavily on high-quality, sensitive data for functions like training, inference, and content generation. As agentic AI emerges, ensuring data quality becomes even more critical for enabling sound decision-making and actions by AI systems. Many organizations are already adopting GenAI, with a third of respondents indicating it is either being integrated or is actively transforming their operations.

Organizations Embrace GenAI, Taking on Greater Security Risks Amid Rapid Adoption

As GenAI introduces complex data security challenges and offers strategic opportunities to strengthen defenses, its growing integration marks a shift among organizations from experimentation to more mature, operational deployment. While most respondents said rapid adoption of GenAI is their top security concern, respondents in the more advanced stages of AI adoption aren’t waiting to fully secure their systems or optimize their tech stacks before forging ahead. Because the drive to achieve rapid transformation often outweighs efforts to strengthen organizational readiness, these organizations may be inadvertently creating their own biggest security vulnerabilities.

“The fast-evolving GenAI landscape is pressuring enterprises to move quickly, sometimes at the cost of caution, as they race to stay ahead of the adoption curve,” Eric Hanselman, Chief Analyst at S&P Global Market Intelligence 451 Research, said. “Many enterprises are deploying GenAI faster than they can fully understand their application architectures, compounded by the rapid spread of SaaS tools embedding GenAI capabilities, adding layers of complexity and risk.”

Seventy-three percent of respondents report investing in AI-specific security tools, either through new budgets or by reallocating existing resources. Those prioritizing AI security are diversifying their approaches: over two-thirds have acquired tools from their cloud providers, three in five are leveraging established security vendors, and nearly half are turning to new or emerging startups. Notably, security for generative AI has quickly risen as a top spending priority, securing the second spot in ranked-choice voting, just behind cloud security. This shift underscores the growing recognition of AI-driven risks and the need for specialized defenses to mitigate them.

Data Breaches Show Modest Decline, Though Threats Remain Elevated

While data breaches remain a significant concern, their frequency has slightly decreased over the past few years. In 2021, 56% of surveyed enterprises reported experiencing a breach, but that figure has dropped to 45% in 2025. Additionally, the percentage of respondents reporting a breach within the last 12 months has fallen from 23% in 2021 to just 14% in 2025.

Malware continues to lead as the most prevalent threat, maintaining its top position since 2021. Phishing climbed to second place, overtaking ransomware, which now ranks third. When it comes to the most concerning threat actors, external sources dominate—hacktivists hold the top spot, followed by nation-state actors. Human error, while still significant, has dropped to third, down one position from the previous year.

Vendors Pressed on Post-Quantum Readiness as Encryption Strategies Are Reassessed

The 2025 Thales Data Threat Report reveals that most organizations are increasingly concerned about quantum-related security risks. The top threat, cited by 63% of respondents, is future encryption compromise—the risk that quantum computers could eventually break current or future encryption algorithms, exposing data once considered secure. Close behind, 61% identified key distribution vulnerabilities, where quantum advancements could undermine the secure exchange of encryption keys. Additionally, 58% highlighted the “harvest now, decrypt later” (HNDL) threat, where encrypted data intercepted today could be decrypted in the future. In response, half of organizations are assessing their encryption strategies, and 60% are actively prototyping or evaluating post-quantum cryptography (PQC) solutions. Only one-third, however, are placing their trust in telecom or cloud providers to manage the transition.

“The clock is ticking on post-quantum readiness. It’s encouraging that three out of five organizations are already prototyping new ciphers, but deployment timelines are tight and falling behind could leave critical data exposed,” Todd Moore, Global Vice President, Data Security Products at Thales, said. “Even with clear timelines for transitioning to PQC algorithms, the pace of encryption change has been slower than expected due to a mix of legacy systems, complexity, and the challenge of balancing innovation with security.”

While this year’s survey results indicate improvements in security posture, much more is needed to elevate operational data security to fully support the capabilities of emerging technologies such as GenAI and to pave the way for future innovations.

For more information please join our webinar hosted by Eric Hanselman, Chief Analyst at S&P Global 451 Research.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

1 This finding relates to the fast changes in the GenAI ecosystem which encompasses the full set of vendors and technologies in GenAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520290850/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye